CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies Closure of Iatrogenic Atrial Septal Defect Following Transcatheter Mitral Valve Repair: The Randomized MITHRAS Trial Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation: A Randomised Non-Inferiority Trial Benefits with drug-coated balloon as compared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: a comprehensive meta-analysis of 45 randomized trials Association Between Malignant Mitral Valve Prolapse and Sudden Cardiac Death: A Review Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs Thrombotic Risk and Antithrombotic Strategies After Transcatheter Mitral Valve Replacement Italian Society of Interventional Cardiology (GIse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO): Impact of Valve Disease Etiology and Residual Mitral Regurgitation after MitraClip Implantation Transcatheter Interventions for Tricuspid Valve Disease: What to Do and Who to Do it On Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis
|<<... 164 165 166 167 168 169 170 ...>>|

Clinical Trial2020 Nov 11.

JOURNAL：Circulation. Article Link

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

SD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al. Keywords: cardiorenal outcomes; empagliflozin

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top